DBVTechnologies

DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on immunotherapy. Co.'s therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to immune systems through intact skin using a platform called Viaskin. Viaskin is an electrostatic patch that offers a self-administered, non-invasive immunotherapy to patients. Once applied on intact skin, Viaskin forms a condensation chamber that hydrates the skin and solubilizes the antigen, allowing it to penetrate the epidermis, where it's captured by Langerhans cells. Co.'s patients include infants and children suffering from severe food allergies.
  • TickerDBV
  • ISINFR0010417345
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Alfred Glaser ...
  • Delphine Brault
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 03/06/2019

...

Victor Floc’h

DBV TECHNOLOGIES: Reorganisation in progress | BUY | EUR46

DBV TECHNOLOGIES - BUY | EUR46(+237%) Reorganisation in progress Significant reduction of cash burn in Q4 2018 Changes in leadership team but no cost saving plan Recent publications from Aimmune DBV is heading towards BLA filing in Q3

Alfred Glaser ...
  • Delphine Brault
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 06/03/2019

...

Martial Descoutures ...
  • Pierre Corby

DBV Technologies : Financial visibility out to Q4 2019

>Limited financial visibility - Yesterday evening after market, the French biopharmaceutical group published its financial results for 2018. The cash position fell short of our expectations at € 122.8m vs our forecast of € 135m. Cash burn stood at € 145.8m for 2018, up +12% vs 2017. We note a not insignificant increase in operational revenue at € 14.5m vs € 11.9m in 2017 due to both a tax credit on research and operating revenue booked over the period linked to t...

Victor Floc’h

DBV TECHNOLOGIES: Reorganisation in progress | BUY | EUR46

DBV TECHNOLOGIES - BUY | EUR46(+237%) Reorganisation in progress Significant reduction of cash burn in Q4 2018 Changes in leadership team but no cost saving plan Recent publications from Aimmune DBV is heading towards BLA filing in Q3

Martial Descoutures ...
  • Pierre Corby

DBV Technologies : Financial visibility out to Q4 2019

>Limited financial visibility - Yesterday evening after market, the French biopharmaceutical group published its financial results for 2018. The cash position fell short of our expectations at € 122.8m vs our forecast of € 135m. Cash burn stood at € 145.8m for 2018, up +12% vs 2017. We note a not insignificant increase in operational revenue at € 14.5m vs € 11.9m in 2017 due to both a tax credit on research and operating revenue booked over the period linked to t...

Martial Descoutures ...
  • Pierre Corby

DBV Technologies : Une visibilité financière jusqu’au T4 2019

>Une visibilité financière limitée - La société biopharmaceutique française publiait hier soir après marché ses résultats financiers 2018. La position de trésorerie ressort en dessous de nos attentes à 122.8 M€ vs 135 M€e. La consommation de trésorerie a atteint 145.8 M€ sur cette dernière année, en hausse de 12% vis-à-vis de 2017. Nous observons une hausse non négligeable des produits opérationnels qui ressort à 14.5 M€ vs 11.9 M€ en 2017 expliquée à la fois par...

Jean-Jacques Le Fur

DBV TECHNOLOGIES: Building-up a newsflow until BLA resubmission expected in Q3 19 | BUY | EUR46

DBV TECHNOLOGIES - BUY | EUR46(+280%) Building-up a newsflow until BLA resubmission expected in Q3 19 Resubmission of the BLA with the FDA in Q3 19 Limited risk that the second review will focus on clinical modules Efficiency program to be communicated alongside FY18 results Newsflow building-up nicely in H1 19

Martial Descoutures ...
  • Pierre Corby

DBV Technologies : New filing scheduled for Q3 2019

>A bit more visibility - DBV Technologies yesterday gave another update on progress with the filing for Viaskin Peanut. The company now expects to resubmit a filing in Q3 this year. In December, DBV withdrew its initial filing in the treatment of children aged 4 to 11 allergic to peanuts. This setback was due to requests from the FDA for further information on the product manufacturing process and quality controls. Fewer than 20 questions, mainly focusing on thes...

1 director sold

A director at Dbv Technologies sold 30,000 shares at 33.090EUR and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names ...

Alfred Glaser ...
  • Delphine Brault
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 03/06/2019

...

Alfred Glaser ...
  • Delphine Brault
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 06/03/2019

...

Ahmed Ben Salem ...
  • Alfred Glaser
  • Aurelien Sivignon
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Jean-François Granjon
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 02/14/2019

...

Ahmed Ben Salem ...
  • Alfred Glaser
  • Aurelien Sivignon
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Jean-François Granjon
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 14/02/2019

...

Martial Descoutures ...
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 12/20/2018

...

DBV TECHNOLOGIES sees an upgrade to Slightly Negative thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to DBV TECHNOLOGIES (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date February 19, 2019, the closing price was EUR 13.57 and its target price was estimated at EUR 5.62.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

DBV Technologies - Assemblée générale des actionnaires du 24 mai 2019

Proxinvest publiera une étude analysant les résolutions proposées lors de la tenue de l’assemblée générale des actionnaires. Vous pouvez l'acquérir dès à présent et elle vous sera adressée par ResearchPool une fois publiée.

Jehanne Leroy

Proxy Report - 22/06/2018

La société propose un vote sur les politiques de rémunérations 2018 des dirigeants (résolutions 16 à 18). Cependant, elle ne présente pas les montants en jeu pour ledit exercice, rendant ainsi impossible toute estimation des montants totaux en jeu ou de la structure de rémunération mise en place par la société. De la même façon, la société propose d'approuver les rémunérations 2017 de ses dirigeants mais ne communique ni la nature des indicateurs utilisés dans le cadre du calcul du bonus annuel ni leurs taux de réalisation individuels, rendant impossible pour l'actionnaire de comprendre comme...

Matthieu DRIOL

Analyse court terme - DBV TECHNOLOGIES : Les prix baissent.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 31,00 €. La tendance baissière serait remise en cause au-dessus de 45,50 €.

Matthieu DRIOL

Short term view - DBV TECHNOLOGIES : Falling prices.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €31.00. The bearish trend would be challenged above €45.50.

Matthieu DRIOL

Analyse court terme - DBV TECHNOLOGIES : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 31,00 €. La tendance baissière serait remise en cause au-dessus de 45,50 €.

Matthieu DRIOL

Short term view - DBV TECHNOLOGIES : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €31.00. The bearish trend would be challenged above €45.50.

Jérôme VINERIER

Analyse moyen terme - DBV TECHNOLOGIES : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 28,40 €, puis 21,60 €. Le franchissement de 47,40 € remettrait en cause la suite de la baisse.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch